Abstract:Background11ß–hydroxysteroid dehydrogenase type1 (11β-HSD1) converts inactive glucocorticoids to active glucocorticoids which, in excess, leads to development of the various risk factors of the metabolic syndrome. Recent studies clearly suggest that both increased expression and activity of 11β-HSD1 in metabolically active tissues such as liver, muscle and adipose are implicated in tissue specific dysregulation which collectively contribute to the whole body pathology seen in metabolic syndrome. In the present study we have evaluated CNX-010-49, a highly potent, selective and ‘pan tissue’ acting 11β-HSD1 inhibitor, for its potential to modulate multiple risk factors of the metabolic syndrome.MethodsMale C57B6/J mice on high fat diet (DIO mice) were orally dosed with CNX-010-49 (30 mg/kg twice daily; n = 8) or vehicle for 10 weeks. Fasting glucose, triglycerides, glycerol, free fatty acids, body weight and feed intake were measured at selected time points. At the end of the treatment an OGTT and subsequently organ histology was performed. In vitro, CNX-010-49 was evaluated in 3T3-L1 preadipocytes to assess impact on adipocytes differentiation, hypertrophy and lipolysis whereas in fully differentiated C2C12 cells and in primary mouse hepatocytes to assess the impact on glucose metabolism and hepatic glucose output respectively.ResultsCNX-010-49 a highly potent and selective pan tissue acting 11β-HSD1 inhibitor (EC50 = 6 nM) significantly inhibits glucocorticoids and isoproterenol mediated lipolysis in mature 3T3-L1 adipocytes, improves muscle glucose oxidation, reduces proteolysis and enhances mitochondrial biogenesis. Also a significant inhibition of gluconeogenesis in primary mouse hepatocytes was observed. The treatment with CNX-010-49 resulted in a significant decrease in fasting glucose, improved insulin sensitivity and glucose tolerance. Treatment also resulted in a significant decrease in serum triglycerides levels and a complete inhibition of body weight gain without affecting feed consumption. A significant reduction in the serum biomarkers like Plasminogen activator inhibitor-1 (PAI-1), interleukin 6 (IL-6) and Fetuin-A with CNX-010-49 treatment was observed indicating a potential to modulate processes implicated in cardiovascular benefits.ConclusionsThese results indicate that inhibition of 11β-HSD1 with CNX-010-49 can give a potential benefit in the management of metabolic dysregulations that are seen in type 2 diabetes.

Novel Curcumin Derivative CNB-001 Mitigates Obesity-Associated Insulin Resistance

A Novel Neuroprotective Curcuminoid Alleviates Glucose Intolerance and Improves Insulin Signaling

Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of hepatic PI3K-AKT axis and IDE, and preservation of islet integrity

A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits

Curcumin Improves Insulin Sensitivity and Increases Energy Expenditure in High-Fat-diet–induced Obese Mice Associated with Activation of FNDC5/irisin

The Novel Mechanism of Recombinant Human Ciliary Neurotrophic Factor on the Anti-Diabetes Activity.

Curcumin Rescues High Fat Diet-Induced Obesity and Insulin Sensitivity in Mice Through Regulating SREBP Pathway.

Curcumin Improved Glucose Intolerance, Renal Injury, and Nonalcoholic Fatty Liver Disease and Decreased Chromium Loss through Urine in Obese Mice

Cyanidin 3-Glucoside Attenuates Obesity-Associated Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed and Db/db Mice Via the Transcription Factor FoxO1.

Targeted Screening of Curcumin Derivatives as Pancreatic Lipase Inhibitors Using Computer-Aided Drug Design

Novel Curcumin Analog C66 Prevents Diabetic Nephropathy Via JNK Pathway with the Involvement of P300/cbp-Mediated Histone Acetylation.

Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation

Novel anti-diabetic effect of SCM-198 via inhibiting the hepatic NF-κB pathway in db/db mice.

Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice.

Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis

The Underlying Mechanisms of Curcumin Inhibition of Hyperglycemia and Hyperlipidemia in Rats Fed a High-Fat Diet Combined with STZ Treatment.

Tetradecyl 2,3-Dihydroxybenzoate Improves the Symptoms of Diabetic Mice by Modulation of Insulin and Adiponectin Signaling Pathways

A Novel Polyphenol-Rich Combination Of 5 Plant Extracts Prevents High-Fat Diet-Induced Body Weight Gain By Regulating Intestinal Macronutrient Absorption In Mice.

Curcumin intervention in hippocampal atrophy of diet-induced Alzheimer-like deficits in insulin-resistant rats

Structural Variances in Curcumin Degradants: Impact on Obesity in Mice

Dietary curcumin restores insulin homeostasis in diet-induced obese aged mice